Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

92.76 +1.32 (+1.44%)
Streaming Delayed Price Updated: 12:56 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 Next >
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
The nosebleed trailing-12-month price-to-earnings ratios for these supercharged growth stocks fails to tell the full story. 
Via The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
 
Via Benzinga
Preview: Biomarin Pharmaceutical's Earnings
 
Via Benzinga
Analyst Ratings for Biomarin Pharmaceutical
 
Via Benzinga
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Biomarin Pharmaceutical
 
Via Benzinga
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
 
Via Benzinga
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition. 
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
The company is testing a drug for children with achondroplasia, a cause of dwarfism. 
Via Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier. 
Via Investor's Business Daily
uniQure Stock Trying To Close In On Key Technical Measure
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
 
Via Benzinga
6 Analysts Have This to Say About Biomarin Pharmaceutical
 
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
Some stocks are hitting new highs. 
Via The Motley Fool
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
 
Via Benzinga
3 Prime Healthcare Takeover Targets
These three companies are attractive targets for their potential. 
Via The Motley Fool
Moderna Stock Getting Closer To Key Technical Benchmark
On Friday, biotech Moderna stock received an upgrade to its Relative Strength (RS) Rating, to 72 from 69 a day earlier. 
Via Investor's Business Daily
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
Cramer Is Holding This Biotech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN). 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
Vertex Pharmaceuticals Stock Sees Rising Relative Strength
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
BioMarin's Growth Prospects Soar with Potential Voxzogo and Roctavian Launches, Analyst Raises Price Target
 
Via Benzinga
Top Picks For 2023: Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about! 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.